BEACON-IPF
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Pliant Therapeutics; Q3 2025 financial results; PLN-101095; oncology program; BEACON-IPF trial; net loss; research and development expenses; cash reserves; Oxford Finance loan repayment
Pliant Therapeutics Discontinues Phase 2b/3 Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis Due to Safety Concerns
Pliant Therapeutics, bexotegrast, BEACON-IPF trial, idiopathic pulmonary fibrosis (IPF), safety concerns, clinical trial discontinuation
Pliant Therapeutics Halts Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial Following Safety Committee Recommendation
Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis (IPF), BEACON-IPF trial, clinical trial suspension, Data Safety Monitoring Board (DSMB)
Pliant Therapeutics Halts Key Fibrosis Drug Trial, Stock Plummets Amid Uncertainty
Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis, BEACON-IPF trial, clinical trial pause, stock crash, Data Safety Monitoring Board